17. A therapeutic method for improving bone metabolism in a human or animal subject comprising:
selecting a human or animal having a tendency toward a decrease in bone density, and therapeutically administering to said human or animal subject fermented soy milk which is obtained by fermenting soy milk with one or more microorganisms selected from the group consisting of Lactobacillus casei, Lactobacillus mali, and Bifidobacterium breve.
18. The method of Claim 17, wherein said subject is human.
19. The method of Claim 17, wherein said subject has osteoporosis.
20. The method of Claim 17, wherein said subject is a postmenopausal female.
25. The therapeutic method of Claim 17, wherein said subject is a human affected with osteoporosis and said subject is administered 100 to 1,000 g per day of a fermented soy milk having a soybean solid component content of at least 6%.
The claims stand rejected as follows:
• Claims 17 and 19-23 under 35 U.S.C. § 102(b) as anticipated by Kikuchi-Hayakawa, 2 as evidenced by Yamaguchi 3 and Potter.
• Claim 18 under 35 U.S.C. § 103 as unpatentable over KikuchiHayakawa, Harrison, 5 and Hayakawa.
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• Claim 25 under 35 U.S.C. § 112, first paragraph, as lacking written descriptive support (new matter).
• Claim 25 under 35 U.S.C. § 112, second paragraph, as indefinite.
We affirm the anticipation and obviousness rejections, and reverse the new matter and indefiniteness rejections.
ANTICIPATION

Issue
The Examiner rejected claims 17 and 19-23 as anticipated by KikuchiHayakawa, as evidenced by Yamaguchi and Potter.
The Examiner finds that Kikuchi-Hayakawa administers fermented soy milk to ovariectomized rats, which have a tendency toward a decrease in bone density, and therefore inherently discloses a therapeutic method for improving bone metabolism (Ans. 4-5).
Appellants contend that Kikuchi-Hayakawa doesn't disclose "a therapy for treating a decrease in bone density" because the rats "were not selected for a tendency toward a decrease in bone density, but rather to determine the effects of soy milk products on lipid metabolism" (App. Br. 10). (Kikuchi-Hayakawa 1688), which are more easily absorbed than the glycosides (id., at 1691).
FF3 Yamaguchi teaches that ovariectomizing rats induces bone loss, and that administering vitamin K 2 , which is "highly contained in the fermented soybean (natto)," prevents this bone loss (Yamaguchi 23). therefore, "would necessarily bring about the recited effect, i.e., therapeutic improvement in bone metabolism" (id. at 9 (emphasis omitted)).
FF6
In addition, the Examiner finds, based on the evidence provided by Yamaguchi and Potter, that Kikuchi-Hayakawa's aged, ovariectomized, estrogen-deficient rats "qualify as animals having osteoporosis" (Ans. 5),
and as non-menstruating postmenopausal females (id. at 4).
Principles of Law
"To anticipate a claim, a prior art reference must disclose every limitation of the claimed invention, either explicitly or inherently." In re Schreiber, 128 F.3d 1473 , 1477 (Fed. Cir. 1997 Appellants contend that Kikuchi-Hayakawa's ovariectomized rats "were not selected for a tendency toward a decrease in bone density, but rather to determine the effects of soy milk products of lipid metabolism" (App. Br. 10), therefore, Kikuchi-Hayakawa's method "is not a therapy for treating a decrease in bone density as required by claim 17" (id.).
Appellants' argument is not persuasive. There is no dispute that Kikuchi-Hayakawa discloses administering fermented soy milk to ovariectomized rats (FF1). The Examiner has provided unrefuted evidence establishing that ovariectomized rats exhibit a decrease in bone density (FF3), i.e., that ovariectomized rats have "a tendency toward a decrease in 
Conclusions of Law
Appellants have not shown that the Examiner erred in finding that
Kikuchi-Hayakawa discloses a therapeutic method for improving bone metabolism by administering fermented soy milk to an animal having a tendency toward bone loss. Nor have Appellants established that the Examiner erred in finding that Kikuchi-Hayakawa's animal subjects were not post-menopausal females with osteoporosis. have a high risk of coronary heart disease, which has been found to be at least partially attributable to an unfavorable lipid metabolism" (KikuchiHayakawa 1688), and that "[t]he potential roles of dietary soy in prevention and treatment of chronic diseases, notably heart disease and cancer, have long been known" (id.).
FF8 Kikuchi-Hayakawa discloses administering fermented soy milk to ovariectomized, estrogen-deficient rats, but doesn't disclose administering it to human subjects. FF11 Hayakawa teaches that soy milk fermented by Bifidobacterium lacks the "distinctive unpleasant odor and taste" of unfermented soy milk, and "has excellent lipid metabolism-improving effects" (Hayakawa 3).
Analysis
Appellants contend that " [t] here is no motivation to modify the method of Kikuchi-Hayakawa to administer fermented soy milk to a human having decreased bone metabolism because the prior art does not suggest that fermented soy milk also induces a greater effect (if at all) for bone metabolism improvement as it does for plasma cholesterol level compared to soy milk" (App. Br. 11).
This argument is not persuasive. 
Conclusions of Law
Appellants have not established that the Examiner erred in concluding that it would have been obvious to administer fermented soy milk to a human subject with a tendency toward bone loss, given the teachings of Kikuchi-Hayakawa, Harrison, and Hayakawa.
WRITTEN DECRIPTION
The Examiner rejected claim 25 as lacking written descriptive support. According to the Examiner, the limitation "fermented soy milk having a soybean solid component content of 'at least 6%'" is new matter (Ans. 7).
Additional Findings of Fact
FF12
The Specification, as originally filed, teaches that "[t]he fermented soy milk can be used as is, [or] concentrated to a certain degree" (Spec. 7: 5-6), it can be provided in "liquid, paste, or solid" form (id. at 7:
Appeal 2009-006581 Application 10/398,507 11 4), and that "fermented soy milk having a soybean solid content of 6% is ingested in an amount of 10-1,000 g a day per person" (id. at 7: 9-10).
Analysis
We will reverse this rejection. We agree with Appellants that "the application conveys to a person of skill in the art that the applicants had possession of the claimed invention" (Reply Br. 2). The Specification, as originally filed, discloses administering fermented soy milk with a soybean solid content of 6% in variable amounts (10-1,000 g a day per person), and in various forms (FF12). We agree that one of skill in the art would understand from the Specification that variable percentages of solids, i.e., higher percentages of solids, were contemplated as well.
INDEFINITENESS
The Examiner rejected Claim 25 as indefinite because it "lack [s] proper antecedent basis in the limitation: 'a fermented soy milk'" (Ans. 4).
We will reverse this rejection as well. We agree with Appellants that one of skill in the art would understand that claim 25 "is directed to administering the same fermented soy milk as that recited in claim 17" from which it depends (Reply Br. 3).
SUMMARY
•
The rejection of claims 17 and 19-23 under 35 U.S.C. § 102(b) as anticipated by Kikuchi-Hayakawa is affirmed.
• The rejection of claim 18 under 35 U.S.C. § 103 as unpatentable over Kikuchi-Hayakawa, Harrison, and Hayakawa is affirmed.
